Novartis sues Biocon for patent infringement on Galvus

Written By Unknown on Kamis, 03 April 2014 | 08.11

In yet another patent infringement battles in India, Swiss drug maker Novartis has taken Indian biotech firm Biocon to court on anti-diabetes drug. Novartis has sued Biocon in Delhi HC on patent infringement on Galvus, chemical name Vildagliptin, and the court has ruled partly in its favour reports CNBC TV18's Archana Shukla.

In yet another patent infringement battles in India, Swiss drug maker Novartis has taken Indian biotech firm  Biocon to court on anti-diabetes drug. Novartis has sued Biocon in Delhi HC on patent infringement on Galvus, chemical name Vildagliptin, and the court has ruled partly in its favour reports CNBC TV18's Archana Shukla.

Glavus is also marketed in combination with Metformin Hydrochloride, owned by Novartis in India.

Novartis's case stems from the fact that Biocon had sought & received approval from the Indian drug regulator CDSCO for its version of Vildagliptin. Novartis argued that Glavus is a novel molecule and patent protected in India. Hence any possible launch by Biocon would infringe on Novartis' patent on that drug.  

Based on the arguments placed on March 28th the Delhi High court ordered that Biocon cannot commercially launch Vildagliptin in India. Although the court said Biocon could manufacture Vildagliptin for in-house research purposes.

Novartis's Galvus is also under another patent battle with Wockhardt . On March 24th the Swiss drug maker had received an injunction against Wockhardt in the Delhi High Court for this product.

Biocon stock price

On April 01, 2014, Biocon closed at Rs 431.10, up Rs 7.05, or 1.66 percent. The 52-week high of the share was Rs 497.40 and the 52-week low was Rs 264.45.


The company's trailing 12-month (TTM) EPS was at Rs 14.01 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 30.77. The latest book value of the company is Rs 110.34 per share. At current value, the price-to-book value of the company is 3.91.


Anda sedang membaca artikel tentang

Novartis sues Biocon for patent infringement on Galvus

Dengan url

https://citraasa.blogspot.com/2014/04/novartis-sues-biocon-for-patent.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Novartis sues Biocon for patent infringement on Galvus

namun jangan lupa untuk meletakkan link

Novartis sues Biocon for patent infringement on Galvus

sebagai sumbernya

0 komentar:

Posting Komentar

techieblogger.com Techie Blogger Techie Blogger